Dr. Tempero on Pancreatic Cancer Immunotherapies
Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the outlook for immunotherapies in pancreatic cancer.
Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the outlook for immunotherapies in pancreatic cancer.
Immunotherapies in this space is a work in progress, Tempero admits. Investigators at Johns Hopkins University School of Medicine have been looking at an autologous cell-based vaccine. Antigen-specific vaccines are in development in pancreatic cancer as well, Tempero says.
There is a need to “make room” for immunotherapies and determine their optimal use, especially with regard to immune checkpoint inhibitors, such as PD-1 and anti-CTLA-4.
